Hexima Limited

HXL

AU0000111932

Biotechnology & Medical Research

Market Closed - Australian Stock Exchange Other stock markets 10:25:24 2023-11-02 pm EDT			5-day change	1st Jan Change
0.0230 ^AUD	+9.52%		0.00%	+15.00%

Sep. 19	Hexima Limited Appoints Phillip Hains as A Non-Executive Director	CI
Sep. 06	Hexima Limited Appoints Geoffrey Kempler as Managing Director	CI

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Hexima Limited

Hexima Limited Appoints Phillip Hains as A Non-Executive Director	Sep. 18	CI
Hexima Limited Appoints Geoffrey Kempler as Managing Director	Sep. 05	CI
Hexima Limited Announces Executive Changes	Sep. 05	CI
Hexima Limited Reports Earnings Results for the Full Year Ended June 30, 2023	Aug. 31	CI
Hexima Limited Announces Resignation of Mr. Steven Skala as an Alternate Director	May. 11	CI
Hexima Limited Reports Earnings Results for the Half Year Ended December 31, 2022	Feb. 27	CI
Hexima Limited Declares Voting Results	Jan. 30	CI
Arovella Therapeutics Appoints COO	Jan. 03	MT
Hexima Acting CEO to Step Down	Dec. 22	MT
Nicole Van Der Weerden to Step Down as CEO of Hexima Limited	Dec. 22	CI
Hexima Receives AU$6 Million Tax Incentive Refund from Australian Taxation Office	Dec. 14	MT
Hexima Limited Receives Requisition Notice from Merchant Biotech Fund	Dec. 13	CI
Hexima Limited Announces Board Changes	Dec. 04	CI
10,150,000 Options of Hexima Limited are subject to a Lock-Up Agreement Ending on 1-DEC-2022.	Nov. 30	CI
6,925,878 Ordinary Shares of Hexima Limited are subject to a Lock-Up Agreement Ending on 1-DEC-2022.	Nov. 30	CI
Hexima Limited Announces Change of Address	2022	CI
Hexima Limited Reports Earnings Results for the Full Year Ended June 30, 2022	2022	CI
Hexima Managing Director, CEO Steps Down	2022	MT
Hexima Limited Announces Management Changes	2022	CI
Hexima Limited Announces Phase II Results of Pezadeftide	2022	CI
Australian Shares Jump on IT Boost Amid Bargain Hunting	2022	MT
Hexima to Conduct Detailed Review of Pezadeftide Phase 2 Trial Data after 'Inconclusive' Results; Shares Plummet 78%	2022	MT
Hexima Limited Announces Preliminary Results of Phase II Clinical Study of Pezadeftide	2022	CI
Hexima Limited Reports Earnings Results for the Half Year Ended December 31, 2021	2022	CI
Hexima Appoints Commercial Chief	2022	MT

Hexima Limited is an Australia-based clinical-stage, anti-infectives focused biotechnology company. The Company is engaged in the research and development of plant defensin peptides for applications in human therapeutics. Its lead drug candidate is the plant defensin, pezadeftide, developed for the treatment of fungal nail infections. The Company is conducting phase II clinical trial testing pezadeftide as a treatment for onychomycosis. Its Antifungal Plant Defensin Technology platform is engaged in identifying several plant peptides with potent antifungal activity against a broad range of human fungal pathogens. It is also investigating the application of its plant defensin technology to other human fungal diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-02-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi. (M$)
HEXIMA LIMITED	+15.00%	3 M $
SEAGEN INC.	+66.81%	40 453 M $
IQVIA HOLDINGS INC.	+2.95%	38 458 M $
MODERNA, INC.	-56.68%	29 633 M $
LONZA GROUP AG	-25.18%	29 066 M $
ICON PUBLIC LIMITED COMPANY	+38.10%	22 180 M $
ALNYLAM PHARMACEUTICALS, INC.	-32.06%	19 978 M $
CELLTRION, INC.	+2.80%	17 370 M $
UNITED THERAPEUTICS CORPORATION	-17.31%	10 860 M $
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-10.69%	9 987 M $